Clinical trials: Amyotrophic Lateral Sclerosis (ALS), open to volunteers
Alzheimer Disease, Parkinson Disease
hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases
To evaluate the safety and preliminary efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles hUC-MSC-sEV-001 nasal drops in multiple neurodegenerative diseases, including Alzheimer's disease…
- Conditions
- Alzheimer Disease, Parkinson Disease, Lewy Body Dementia, Multiple System Atrophy
- Trial name
- NCT06607900
- Testing
- hUC-MSC-sEV-001 nasal drops
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xuanwu Hospital, Beijing
Amyotrophic Lateral Sclerosis
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration…
- Trial name
- ALS (NCT07287397)
- Testing
- VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 36 people
- Sponsor
- Vector Y Therapeutics
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
The aim of this project is to analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals, patients with other motor impairments) and…
- Trial name
- Mac2ALS (NCT04816227)
- Where
- France
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans
A Study on the Addition of Alsum30 for the Treatment of Amyotrophic Lateral Sclerosis
This single-center, open-label pilot study will enroll approximately 15 adults with amyotrophic lateral sclerosis (ALS) to assess the safety and tolerability of adding Alsum30 to their care.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans, Dietary Supplement, Sulforaphane
- Trial name
- NCT07922031
- Testing
- Sulforaphane and Bacillus coagulans GBI-30, 6086
- Volunteers
- 15 people
- Sponsor
- Liu Qing
Amyotrophic Lateral Sclerosis
Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons, leading to progressive muscle weakness and functional decline.
- Trial name
- NCT07467746
- Testing
- C. cicadae, Control
- Volunteers
- 84 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Amyotrophic Lateral Sclerosis ALS
Intestinal Microbiome Transplant in ALS
This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected.
- Trial name
- NCT07017946
- Testing
- MTP-101C
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
Tongue-strengthening Exercises in People With ALS.
This study is testing a tongue exercise program for people living with ALS to see if it can help support speech and swallowing. All participants will receive the treatment, and researchers will measure changes over time by…
- Trial name
- NCT07295990
- Testing
- Isometric Lingual Strength Exercises
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nova Southeastern University
ALS
Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)
Investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (ALS) in Israel with a view to future international collaboration. Particularly addressing:- 1. Differences between ethnic subgroups 2.
- Trial name
- EpidALS (NCT03366506)
- Testing
- Observation
- Where
- Israel
- Volunteers
- 2,000 people
- Sponsor
- Hadassah Medical Organization
Amyotrophic Lateral Sclerosis
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is one of the most lethal neurodegenerative diseases, with most patients dying from respiratory failure 3-5 years after the onset.
- Trial name
- NATURAL (NCT06391645)
- Testing
- Nerve Growth Factor
- Volunteers
- 60 people
- Sponsor
- Beijing Tiantan Hospital
Amyotrophic Lateral Sclerosis, ALS
A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients
FIH, Phase 1/2, multi-centre, randomised, double-blind, placebo controlled study with an optional open-label dosing extension to assess the safety, tolerability, efficacy, and Pharmacodynamics (PD) of single or multiple (up to 48…
- Trial name
- NCT06513546
- Volunteers
- 153 people
- Sponsor
- PLL TX AUSTRALIA PTY LTD
ALS (Amyotrophic Lateral Sclerosis)
Virtual Reality for Anxiety Management in Persons With Amyotrophic Lateral Sclerosis
Virtual Reality (VR) is gaining traction as a new and innovative leisure to augment healthcare services. Several benefits of the leisure experience, such as distraction and full sensory immersion, have demonstrated a potential to…
- Trial name
- VR ALS (NCT07473765)
- Testing
- Virtual Reality Guided Breathing Exercise
- Volunteers
- 60 people
- Sponsor
- Horizon Health Network
Amyotrophic Lateral Sclerosis
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)
In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for participant with a certain type of amyotrophic lateral sclerosis, also known…
- Trial name
- NCT07259980
- Testing
- Tofersen
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
The National Amyotrophic Lateral Sclerosis Registry
The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be…
- Trial name
- NCT01772602
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Centers for Disease Control and Prevention
Amyotrophic Lateral Sclerosis
Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
1. Describe the distribution of ALS in mainland China, to explore the differences in the number of ALS in different times, regions and populations in order to further explore the causes affecting the distribution of ALS; 2.
- Trial name
- NCT04454892
- Testing
- Amyotrophic lateral sclerosis
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis, Neuromuscular Disease
Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)
The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI).
- Conditions
- Amyotrophic Lateral Sclerosis, Neuromuscular Disease, Stroke, Tetraplegia/Tetraparesis
- Trial name
- CONNECT-ONE (NCT07357428)
- Testing
- Connexus Brain-Computer Interface
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Paradromics
Amyotrophic Lateral Sclerosis (ALS)
Identification of Early Markers for ALS
Although several molecules have been proposed as biomarker candidates, a clinically established signature for an early or even premotor diagnosis of ALS is not available.
- Trial name
- PremodiALS (NCT07213440)
- Testing
- lumbar puncture
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
ALS, ALS (Amyotrophic Lateral Sclerosis)
Healey ALS MyMatch Common Screening Protocol
The goal of the Healey ALS MyMatch Common Screening Protocol (MCSP), an observational study, is to identify individuals with ALS who may be eligible to be matched to a currently enrolling ALS MyMatch trial.
- Conditions
- ALS, ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
- Trial name
- MCSP (NCT07400393)
- Volunteers
- 500 people
- Sponsor
- Massachusetts General Hospital